Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium
暂无分享,去创建一个
B. Teicher | P. Houghton | Malcolm A. Smith | R. Gorlick | D. Harrison | R. Kurmasheva | E. Kolb | Wendong Zhang | Michael E. Roth | S. Erickson | Zhong-Fa Zhang | G. Gatto | Jonathan Gill | Sudie Rowshan
[1] Andrew J. Robles,et al. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts , 2020, Clinical Cancer Research.
[2] J. Hainsworth,et al. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2‐negative Breast Cancer , 2019, Clinical breast cancer.
[3] R. Goldsby,et al. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group , 2018, Pediatric blood & cancer.
[4] J. Reid,et al. A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) , 2018, Pediatric blood & cancer.
[5] S. Keir,et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[6] T. Mukohara,et al. Eribulin mesylate in patients with refractory cancers: a Phase I study , 2011, Investigational New Drugs.
[7] Sarika Jain,et al. Eribulin Mesylate , 2011, Clinical Cancer Research.
[8] C. Takimoto,et al. A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies , 2009, Clinical Cancer Research.
[9] J. Khan,et al. Molecular Characterization of the Pediatric Preclinical Testing Panel , 2008, Clinical Cancer Research.
[10] M. Jordan,et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase , 2008, Molecular Cancer Therapeutics.
[11] Joseph Zeidner,et al. The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.
[12] Melvin J. Yu,et al. Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389 , 2004, Cancer Research.
[13] Joseph P. Near,et al. How to cite this article , 2011 .